Exogenous administration of GLP-1 also contributes to the reduction in postprandial glycemic peaks, both in patients with type 2 diabetes and in those with type 1 diabetes, through the effect of delaying the transit of nutrients from the stomach to the small intestine [68]. This evidence concerns the gene GCG and type 2 diabetes mellitus.